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Abstract 
Background: Asthma requires regular follow‑up visits and sustained medication use. Although several studies 
have reported the importance of adherence to medication and compliance with the treatment, none to date have 
reported the importance of regular follow‑up visits. We investigated the effects of regular clinical visits on asthma 
exacerbation.
Methods: We used claims data in the national medical insurance review system provided by the Health Insurance 
Review and Assessment Service of Korea. We included subjects aged ≥ 15 years with a diagnosis of asthma, and who 
were prescribed asthma‑related medication, from July 2013 to June 2014. Regular visitors (frequent visitors) were 
defined as subjects who visited the hospital for follow‑up of asthma three or more times per year.
Results: Among 729,343 subjects, 496,560 (68.1%) were classified as regular visitors. Old age, male sex, lack of medi‑
cal aid insurance, attendance of a tertiary hospital, a high Charlson comorbidity index, and a history of admission 
for exacerbated asthma in the previous year were significant determining factors for regular visitor status. When we 
adjusted for all these factors, frequent visitors showed a lower risk of asthma exacerbation requiring general ward 
admission (odds ratio [OR] 0.48; 95% confidence interval [CI] 0.47–0.50; P < 0.001), emergency room admission (OR 
0.83; 95% CI 0.79–0.86; P < 0.001), and intensive care unit admission (OR 0.49; 95% CI 0.44–0.54; P < 0.001) than infre‑
quent visitors.
Conclusions: Regular clinical visits are significantly associated with a reduced risk of asthma exacerbation requiring 
hospital admission in Korean adults with asthma.
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Background
Asthma is characterized by chronic airway inflammation 
that requires regular followed-up visits and continuous 
medication use [1, 2]. Several studies have reported that 
a large proportion of asthma patients (10–60%) showed 
poor adherence to medication [3–5]. There are numer-
ous reasons for such poor adherence. Some patients pre-
fer to use medication for a shorter period of time, and 
therefore, they do not take medication when they are 
asymptomatic [6–8]. Other reasons include forgetful-
ness, inconvenience, and unawareness of the importance 
of medication [9]. However, many studies have revealed 
that subjects with good adherence to medication use 
were at reduced risk for asthma exacerbation and mor-
tality as compared with subjects with poor adherence 
[10–12]. Therefore, clinicians have attempted to increase 
adherence to obtain a better prognosis by using inhaler 
reminders, good partnership, and intensive patient edu-
cation and training [13, 14].
Regular clinical visits may have increased the oppor-
tunity to increase adherence and compliance. When 
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patients visit clinics frequently, clinicians can pay careful 
attention to the patients, educate them in detail, judge the 
situation more appropriately, and prescribe the proper 
medication. Together, this might lead to an improved 
prognosis; however, to date, there are no data to prove 
this hypothesis. We therefore investigated the hypothesis 
that regular visits would have a protective effect against 
asthma exacerbation, by using a large body of claims data 
from the national medical insurance review system that 
covers most Korean individuals.
Methods
Ethics
This study was approved by the Ethics Committee of 
the National Evidence-Based Healthcare Collaborating 
Agency. The need for informed consent was waived by 
the institutional review board of the Gangnam Severance 
Hospital, Yonsei University Health System (Approval 
Number: 3-2016-0332).
Data sources
Korea has adopted a single mandatory government-
established health insurance system, and the Health 
Insurance Review and Assessment Service (HIRA) is 
an agency responsible for evaluating all medical claim 
data in Korea. As the HIRA has accumulated all medical 
records, most Korean citizens are thought to be covered 
by this system [15]. We retrospectively reviewed and ana-
lyzed the data from the HIRA database of the national 
medical insurance review system of Korea.
Study populations
Patients with asthma were defined as follows, based on 
previous articles that had used HIRA data [15, 16]; this 
was also concordant with the definition used by HIRA for 
the asthma quality evaluation program. We included all 
patients aged ≥ 15 years, with asthma (J45.0, J45.1, J45.8, 
J45.9, J46.0, J46.1, J46.8, or J46.9 from the International 
Classification of Diseases-10th revision) as the principal 
or the first additional diagnosis, from July 2013 to June 
2014. The included patients were prescribed asthma-
related medication (inhaled, oral, or injected) on at least 
two outpatient visits, or on at least one outpatient visit 
along with systemic corticosteroids prescribed on admis-
sion. Asthma-related medications included corticoster-
oids, leukotriene antagonists, long-acting β2-agonists, 
short-acting β2-agonists, anticholinergics, and xanthine 
derivatives.
Definition of terms
Regular visitors (frequent visitors) were defined as sub-
jects who visited the hospital for clinical follow-up of 
asthma three or more times per year, regardless of the 
visit interval and visit site; alternatively, they were clas-
sified as infrequent visitors. The Charlson comorbidity 
index, which is a value facilitating prediction of progno-
sis and mortality based on comorbidities, was calculated 
as previously described [17, 18]. Asthma exacerbation 
requiring hospital admission was defined as an admission 
to a general ward, emergency room (ER), or intensive 
care unit (ICU), with a diagnosis of asthma as the princi-
pal or the first additional diagnosis.
Statistical analysis
We used the t test and Chi square test to identify dif-
ferences in continuous data and categorical variables 
between frequent and infrequent visitors, respectively. 
Univariate and multivariate analyses were used to find 
significant factors for regular visitor status and admission 
with asthma exacerbation, using logistic regression anal-
ysis. We used SPSS v18.0 (IBM Corp, Armonk, NY). A P 
< 0.05 was considered statistically significant.
Results
Demographics of subjects
We reviewed 729,343 subjects enrolled in National 
Health Insurance Database. The mean age of subjects was 
57.2  years, and 40.3% were male. Most subjects (82.2%) 
were followed-up in a primary hospital, while others 
(21.7%) attended a tertiary hospital. Pulmonary function 
tests were performed in 21.2% of subjects. Although data 
was not shown, 11.1% of subjects attended more than two 
hospital types. Most of the subjects (66.2%) had allergic 
rhinitis. Hypertension, diabetes mellitus, and metabolic 
syndrome accompanied asthma in 15.3, 7.7, and 6.5% of 
patients, respectively. The mean Charlson comorbidity 
index was 1.3. Some subjects (2.6%) had experienced at 
least one additional asthma exacerbation requiring hos-
pital admission in the previous year. A total of 68.1% of 
cases were regular visitors (Table 1).
Significant factors for frequent visitors
Frequent visitors were significantly older. The percentage 
of male patients was slightly higher in the frequent visitor 
group, compared with the infrequent visitor group. They 
had less medical aid insurance and frequently attended a 
tertiary hospital. They also had a high Charlson’s comor-
bidity index, and had more frequently experienced 
admission with exacerbated asthma in the previous year, 
as compared to infrequent visitors (Table 2).
We set out to define significant factors that determine 
frequent visitor status. Multivariate analysis confirmed 
that old age (odds ratio [OR] 10.5; 95% confidence inter-
val [CI] 1.01–1.02; P < 0.001), male sex (OR 1.05; 95% CI 
1.04–1.07; P < 0.001), tertiary hospital attendance (OR 
4.97; 95% CI 4.84–5.10; P < 0.001), a higher Charlson 
Page 3 of 7Park et al. Allergy Asthma Clin Immunol  (2018) 14:29 
comorbidity index (OR 1.40; 95% CI 1.39–1.42; P < 0.001), 
and a history of admission with exacerbated asthma in 
the previous year (OR 1.72; 95% CI 1.64–1.80; P < 0.001) 
were significant contributing factors to frequent visi-
tor status. Subjects with medical aid insurance tended 
not to be frequent visitors (OR 0.69; 95% CI 0.68–0.71; 
P < 0.001) (Table 3).
Number of subjects with asthma exacerbation according 
to visit frequency
We compared unadjusted healthcare utilization with 
asthma exacerbation between infrequent and frequent 
visitors. Frequent visitors showed more frequent exacer-
bations requiring admission to the general ward (4.6% vs. 
3.2%; P < 0.001), ER (2.8% vs. 1.2%; P < 0.00), or ICU (0.4% 
vs. 0.3%; P < 0.001) than did infrequent visitors (Table 4).
Regular visits are protective factors against asthma 
exacerbation
Concordant with the results shown in Table 3 in univari-
ate analysis, frequent visitor status was a significant risk 
factor for asthma exacerbation requiring general ward 
admission (OR 1.44; 95% CI 1.40–1.48; P < 0.001), ER 
utilization (OR 2.29; 95% CI 2.20–2.39; P < 0.001), and 
ICU admission (OR 1.54; 95% CI 1.41–1.69; P < 0.001). 
However, we sought to define whether the frequent visits 
increased the risk for or were protective against asthma 
exacerbation in adjusted conditions. In multivariate anal-
ysis, in which we included all the factors significant for 
frequent visitor status, we found the opposite results, as 
follows. Old age, male sex, subjects without medical aid 
insurance, tertiary hospital type attendance, a higher 
Charlson comorbidity index, and admission with exac-
erbated asthma in the previous year were significant 
predictive factors for asthma exacerbation requiring 
admission. Moreover, we found that frequent hospital 
visits was factor protecting against asthma exacerbation 
requiring general ward admission (OR 0.48; 95% CI 
0.47–0.50; P < 0.001), ER utilization (OR 0.83; 95% CI 
0.79–0.86; P < 0.001), and ICU admission (OR 0.49; 95% 
CI 0.44–0.54; P < 0.001) (Table 5).
Table 1 Demographics of subjects
SD standard deviation, CT computed tomography
Parameters N (%)
Age (mean ± SD) 57.2 ± 17.9
Male 293,762 (40.3)
Subjects with medical aid insurance 675,479 (92.6)
Hospital type
 Primary 599,460 (82.2)
 Secondary 56,484 (7.7)
 Tertiary 158,043 (21.7)
Tests subjects were taken
 Chest X‑rays 118,479 (16.2)
 Chest CT 2291 (0.3)
 Pulmonary function test 154,984 (21.2)
Co‑morbidity
 Ischemic heart disease 21,191 (2.9)
 Osteoporosis 16,138 (2.2)
 Depressive disorder 7703 (1.1)
 Arthritis 24,392 (3.3)
 Diabetes mellitus 56,355 (7.7)
 Pneumothorax 716 (0.1)
 Congestive heart failure 10,914 (1.5)
 Hypertension 111,249 (15.3)
 Anemia 7412 (1.0)
 Metabolic syndrome 47,605 (6.5)
 Allergic rhinitis 482,540 (66.2)
Charlson’s comorbidity index (mean ± SD) 1.3 ± 0.7
Subjects admitted with exacerbated asthma in previous 
year
18,899 (2.6)
Frequent visitor 496,560 (68.1)
Total 729,343 (100.0)
Table 2 Differences in patterns between infrequent and frequent visitors
SD standard deviation
Parameters Infrequent visitor Frequent visitor P value
Age (mean ± SD) 52.9 ± 18.5 59.2 ± 17.5 < 0.001
Male 38.9% 40.9% < 0.001
Medical aid insurance 95.1% 91.4% < 0.001
Hospital type < 0.001
 Primary 81.3% 67.4%
 Secondary 4.6% 4.0%
 Tertiary 11.0% 13.8%
Charlson’s comorbidity index (mean ± SD) 1.2 ± 0.5 1.4 ± 0.8 < 0.001
Admission with exacerbated asthma in previous year 1.0% 3.3% < 0.001
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Discussion
This large retrospective population study of asthma 
patients defined significant decisive factors for regular 
hospital visitor status, and demonstrated that regular 
visits were significantly associated with a better asthma 
prognosis. Superficially, regular visits would seem to 
be associated with increased asthma exacerbation, as 
shown in the unadjusted data in Table 2. We first identi-
fied significant decisive factors for regular visitor status, 
although age and male sex are not clinically significant 
factors. Importantly, admission with exacerbated asthma 
in the “previous year” was a significant factor for frequent 
visitor status. Thus, asthma patients who suffered asthma 
exacerbation in the “previous year” may visit the hospi-
tal frequently. Further, we observed acute exacerbation in 
the “next year” in both frequent and infrequent visitors. 
After we controlled for the effect of asthma exacerba-
tion in the “previous year,” including the effects of other 
significant decisive factors on regular visitor status, we 
found that the risk of acute exacerbation in the “next 
year” was reduced in frequent visitors. Regular visits (at 
least three or more times per year) were significantly 
associated with a reduction in the risk of general ward, 
ER, and ICU admission for exacerbated asthma by 52, 17, 
and 51%, respectively, as compared to infrequent hospi-
tal visits. This study therefore revealed that regular visits 
may have protective effects against asthma exacerbation. 
We therefore suggest that clinicians should encourage 
asthma patients to participate in regular and frequent fol-
low-up visits in order to reduce the risk for asthma exac-
erbation requiring admission.
Asthma is a chronic airway disease that requires long-
term follow-up and consistent care. It is advisable to 
encourage patients to attend regular follow-up visits as 
a first step toward achieving a good prognosis. Patients 
require education regarding an asthma action plan [19], 
inhaler technique [20], required changes of medica-
tion dose and frequency [21], and improvement of the 
patient-physician partnership [22], in order to improve 
adherence and compliance, so as to facilitate a good prog-
nosis. Regular visits are a precondition for these factors; 
notably, regular visitors may receive careful attention, be 
educated closely, and be assured that their medication 
is adjusted appropriately. Thus, regular visits will lead 
to increased adherence and compliance, with associated 
improvements in prognosis.
As in many countries, the majority of asthma patients 
are managed at primary hospitals (82.2%) by general 
practitioners in Korea because the initial management of 
asthma can be satisfactorily carried out at a primary hos-
pital. Moreover, the primary hospital is generally more 
accessible, implies lower cost, and greater convenience. 
Table 3 Significant factors contributing to frequent visitor status
OR odds ratio, CI confidence interval
Parameters Univariate analysis Multivariate analysis
OR (95% CI) P value OR (95% CI) P value
Age 1.02 (1.02–1.02) < 0.001 1.01 (1.01–1.02) < 0.001
Male 1.09 (1.08–1.10) < 0.001 1.05 (1.04–1.07) < 0.001
Medical aid insurance 0.55 (0.54–0.56) < 0.001 0.69 (0.68–0.71) < 0.001
Hospital type
 Primary 0.82 (0.81–0.83) < 0.001 3.95 (3.84–4.06) < 0.001
 Secondary 1.55 (1.52–1.58) < 0.001 3.35 (3.25–3.45) < 0.001
 Tertiary 2.25 (2.22–2.28) < 0.001 4.97 (4.84–5.10) < 0.001
Charlson’s comorbidity index 1.71 (1.69–1.72) < 0.001 1.40 (1.39–1.42) < 0.001
Admission with exacerbated asthma in previous year 3.28 (3.14–3.42) < 0.001 1.72 (1.64–1.80) < 0.001
Table 4 Number of subjects with asthma exacerbations, according to visit frequency
ER emergency room, ICU intensive care unit
Parameters Number of subjects experienced asthma  
exacerbation in infrequent visitor (%)
Number of subjects experienced asthma  
exacerbation in frequent visitor (%)
P value
General ward admission 7504 (3.2) 22,697 (4.6) < 0.001
ER admission 2881 (1.2) 13,876 (2.8) < 0.001
ICU admission 596 (0.3) 1958 (0.4) < 0.001
Total 232,783 (100.0) 496,560 (100.0)
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Therefore, the role of the general practitioner at primary 
hospitals in encouraging asthma patients to participate in 
regular and frequent follow-up visits is important.
In Korea, an asthma quality evaluation program was 
launched in 2013, to improve the quality of life of asthma 
patients and achieve a good prognosis. The assess-
ment parameters included the frequency of pulmonary 
function tests, the frequency of prescription of manda-
tory asthma medications (inhaled corticosteroids and/
or anti-leukotriene modifiers) [23], the frequency of 
prescription of non-mandatory asthma medications 
(beta-agonist and/or oral corticosteroids), and regular 
visitor status, which was defined as subjects who visited 
hospitals for asthma three or more times per year. We 
therefore attempted to identify whether regular visits 
facilitated a good prognosis. We used the same definition 
as described in the asthma appropriateness assessment in 
Korea in this study.
The GINA 2016 guidelines recommend that patients 
should preferably be seen 1–3  months for step-up and 
step-down management after starting treatment, and 
thereafter every 3–12  months for maintenance [2]. 
However, there has been no clear evidence to date sup-
porting the necessity of frequent and regular visits. The 
persistence rate for clinic visits is reported to be 65 
and 40% after 3 and 6  months of medication initiation, 
Table 5 Univariate and multivariate analyses for asthma exacerbation requiring admission
OR odds ratio, CI confidence interval, ER emergency room, ICU intensive care unit
Parameters Univariate analysis Multivariate analysis
OR (95% CI) P value OR (95% CI) P value
General ward admission with exacerbated asthma
 Age 1.04 (1.04–1.04) < 0.001 1.02 (1.02–1.02) < 0.001
 Male 1.08 (1.06–1.11) < 0.001 0.79 (0.77–0.81) < 0.001
 Medical aid insurance 0.43 (0.42–0.44) < 0.001 0.81 (0.78–0.85) < 0.001
 Hospital type
  Primary 0.19 (0.19–0.20) < 0.001 1.44 (1.39–1.48) < 0.001
  Secondary 7.75 (7.56–7.95) < 0.001 15.97 (15.40–16.56) < 0.001
  Tertiary 12.25 (11.93–12.58) < 0.001 20.14 (19.44–20.88) < 0.001
 Charlson’s comorbidity index 2.11 (2.09–2.13) < 0.001 1.62 (1.60–1.64) < 0.001
 Admission with exacerbated asthma in previous year 14.16 (13.70–14.63) < 0.001 4.39 (4.22–4.56) < 0.001
 Frequent visitor 1.44 (1.40–1.48) < 0.001 0.48 (0.47–0.50) < 0.001
ER admission with asthma exacerbation
 Age 1.02 (1.02–1.02) < 0.001 0.99 (1.00–1.00) 0.023
 Male 1.44 (1.40–1.48) < 0.001 1.10 (1.07–1.14) < 0.001
 Medical aid insurance 0.48 (0.46–0.050) < 0.001 0.79 (0.75–0.83) < 0.001
 Hospital type
  Primary 0.25 (0.25–0.26) < 0.001 2.03 (1.96–2.11) < 0.001
  Secondary 2.93 (2.82–3.05) < 0.001 4.10 (3.91–4.30) < 0.001
  Tertiary 60.61 (56.91–64.56) < 0.001 77.05 (72.11–82.33) < 0.001
 Charlson’s comorbidity index 1.84 (1.82–1.86) < 0.001 1.38 (1.36–1.40) < 0.001
 Admission with exacerbated asthma in previous year 9.51 (9.11–9.92) < 0.001 2.55 (2.43–2.67) < 0.001
 Frequent visitor 2.29 (2.20–2.39) < 0.001 0.83 (0.79–0.86) < 0.001
ICU admission with asthma exacerbation
 Age 1.08 (1.08–1.08) < 0.001 1.05 (1.05–1.06) < 0.001
 Male 1.55 (1.44–1.68) < 0.001 1.16 (1.07–1.26) < 0.001
 Medical aid insurance 0.39 (0.35–0.43) < 0.001 0.84 (0.75–0.94) 0.002
 Hospital type
  Primary 0.19 (0.17–0.20) < 0.001 1.42 (1.30–1.54) < 0.001
  Secondary 2.33 (2.10–2.59) < 0.001 2.09 (1.87–2.34) < 0.001
  Tertiary 158.04 (121.81–205.04) < 0.001 122.29 (93.79–159.45) < 0.001
 Charlson’s comorbidity index 2.13 (2.09–2.18) < 0.001 1.51 (1.48–1.55) < 0.001
 Admission with exacerbated asthma in previous year 11.68 (10.64–12.82) < 0.001 2.47 (2.23–2.72) < 0.001
 Frequent visitor 1.54 (1.41–1.69) < 0.001 0.49 (0.44–0.54) < 0.001
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respectively [24]. Our findings suggest that asthma 
patients should be followed-up at least every 3–4 months 
(at least three or more times per year), and that this may 
be an easy approach for achieving a favorable prognosis.
The strength of this study was that we included a large 
population, reflecting almost all adults with asthma in 
Korea. The national medical insurance review system 
covers nearly all Korean individuals, and therefore, the 
729,343 subjects enrolled in this study might encompass 
all the asthma patients in Korea. This is also supported by 
a calculation based on an asthma prevalence of about 2% 
and the total population size (about 40 million) in South 
Korea [25]. Therefore, this indicates the trustworthiness 
of the data.
This study has some limitations. First, this is a cross-
sectional observational study, not a cohort study. There-
fore, we cannot firmly conclude that regular visits 
directly reduce asthma exacerbations. We cannot ascer-
tain causality; instead, we suggest that regular visits are 
significantly associated with reduced asthma exacerba-
tions. Second, we could not analyze the potential vari-
ables that affect the frequency of visits and prognosis due 
to the retrospective nature of this study. For instance, 
adherence to medication, the dose of the inhaler, socio-
economic status, clinical characteristics, residential dis-
trict, and weather may be influential factors [26, 27]. In 
this retrospective study, which used claim data from a 
national medical insurance review system, the available 
variables were extremely restricted. Third, we used an 
operational definition for asthma diagnosis and exacerba-
tion. We could not use the results of pulmonary function 
tests, or review the clinical charts of patients. Moreover, 
the operational definition of “asthma exacerbation” used 
in this study may contain a small number of patients who 
were admitted to the hospital for other reasons. This 
operational definition may influence the results; how-
ever, the large number of subjects may overcome this 
bias. Fourth, we could not discriminate mild exacerba-
tions that did not require admission. Outpatients with 
mild exacerbations may visit clinics more frequently, and 
this may be a confounding factor. However, a history of 
exacerbation in previous years, for which we adjusted in 
this study, will also help to overcome this bias. Fifth, we 
cannot ignore collider bias; medication analysis could be 
considered to reveal indirect effects of other variables on 
asthma exacerbations. Last, we did not stratify accord-
ing to the number of visits. Further studies are needed to 
determine an optimal threshold for the number of visits.
Conclusions
This retrospective study, based on a large study popu-
lation, demonstrated that regular clinic visits are sig-
nificantly associated with reducing the risk of asthma 
exacerbation requiring hospital admission by 20–50% in 
Korean adults with asthma. We recommend that clini-
cians encourage asthma patients to participate in regular 
medical visits to achieve a good prognosis.
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